Introduction
It has been suggested that the use of enteric coated prednisolone in place of standard oral prednisolone preparations may be associated with a lower risk of peptic ulceration and aggravation of pre-existing peptic ulcers (West, 1959) . The bioavailability of enteric coated prednisolone and non-enteric coated prednisolone is not significantly different in normal subjects (Morrison, Bradbrook and Rogers, 1977 (Morrison et al., 1977) . Plasma prednisolone levels were measured in this patient following 45-mg enteric coated prednisolone and one day later following 45 mg non-enteric coated prednisolone (Fig. 1) . Plasma prednisolone levels were also measured in a normal volunteer following 10-mg enteric coated prednisolone (Fig. 1) . The enteric coated tablets used for both subjects were from the same batch (Deltacortril,® Pfizer). Figure 1 shows that in the normal volunteer there is a delay (lag time) before prednisolone is detectable in the plasma as might be expected following the enteric coated preparation. Both preparations produced similar peak levels. These results are consistent with previous data on plasma prednisolone levels in normal subjects (Morrison et al., 1977 improvement in clinical response and she was discharged 42 days after admission.
Discussion
This case illustrates the necessity for awareness of possible drug malabsorption. The poor clinical response to prednisolone suggested poor prednisolone absorption. The incomplete cortisol suppression supported this clinical impression. The use of a prednisolone assay indicated impaired bioavailability following the enteric coated preparation but normal bioavailability following the standard oral preparation.
The cause of the enteric coated prednisolone malabsorption in this case remains obscure. As tablets from the same batch showed normal bioavailability in a normal volunteer a batch fault in formulation is unlikely. The patient was concurrently taking Asilone, terbutaline, effervescent potassium, frusemide, penicillin V and amoxycillin. The first 3 drugs together with the stress of her illness would be expected to decrease the gastric-emptying rate causing a delay in peak level but duodenal ulceration is associated with an increased gastric-emptying rate (Nimmo, 1976) . Possibly concurrent administration of Asilone may have sufficiently increased gastric pH to allow slow leakage of prednisolone through the enteric coat thus making the drug available for absorption and thus hepatic first pass metabolism. Malabsorption syndromes can affect drug absorption (Parsons, 1977) byt this patient had no symptoms suggestive of a malabsorption and her daily faecal fat measured over 3 days was 04 mmol (normal range <18 mmol).
Although the cause of the malabsorption of the enteric coated prednisolone is unknown in this patient the enteric coated preparation showed biological inequivalence to the conventional oral preparation. This was confirmed by a basal cortisol level of 45 nmol/l and the development of Cushingoid features when enteric coated prednisolone therapy was replaced by conventional tablets and the dose reduced from 20 mg/day to 2-5 mg/day after discharge. 
